Trial Profile

A Phase 2 Clinical Study of SKB264 With/Without KL-A167 in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-negative Breast Cancer Who Have Not Received Prior Systemic Therapy

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacituzumab Tirumotecan (Primary) ; Tagitanlimab (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms OptiTROP-Breast05
Sponsors Sichuan Kelun-Biotech Biopharmaceutical

24 Apr 2025 According to Kelun Pharmaceutical media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
17 Oct 2023 Number of treatment arms have been increased from 3 to 5 by the addition of 2 more experimental arms.
17 Oct 2023 Planned number of patients changed from 95 to 175.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com